EXOZ news

Exozymes Inc. has entered into a definitive agreement to acquire OLC Technologies, a company specializing in solution-development services, aimed at strengthening its sales channel and proprietary technology offerings.

Spencer Fane LLP affirmed that the securities associated with eXoZymes Inc.'s shelf registration drawdown are legally valid. This opinion confirms the company's compliance with securities regulations, supporting the current issuance of 71,110 shares and 35,555 warrants via Public Ventures.

eXoZymes Inc. received a $2.03 million NIH grant to advance cannabinoid analogs. The funding validates the company's platform amid the rapidly growing minor cannabinoids market.

eXoZymes Inc. completed an underwritten public offering of 330,575 units at $8.99 per share, raising approximately $5.95 million in gross proceeds before expenses. The company plans to use net proceeds for development of its NCT product candidate, advancing other product opportunities, and general c…

eXoZymes Inc. filed an 8-K regarding a shelf drawdown offering of common stock and warrants under Form S-3 registration. The offering includes 592,270 shares and 296,135 warrants with potential over-allotment coverage, with Public Ventures LLC as underwriter.